With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Circulating Repetitive Element RNAs as an Osteosarcoma Marker||Children's Hospital Los Angeles / David Cobrinik, MD/PhD||Innovation Grants||2018||California|
|Blockade of p53 and Aurora A in Therapy Resistant Neuroblastoma||University of California San Francisco / William Clay Gustafson, MD, PhD||'A' Award Grants||2011||California|
|Investigating the Role of Genetic and Epigenetic Variation in Risk of Childhood Acute Lymphoblastic Leukemia in Down Syndrome||University of California San Francisco / Adam de Smith, Ph.D.||'A' Award Grants||2014||California|
|Enhancing Effectiveness of Immune Checkpoint Therapy in Neuroblastoma||Children's Hospital Los Angeles / Shahab Asgharzadeh, MD||Innovation Grants||2015||California|
|Single Cell Signaling Profiles In High-Risk Pediatric Leukemia||Stanford University / Kara Davis||Young Investigator Grants||2010||California|
|Pediatric Developmental Therapeutics Center of Excellence at UCSF||University of California San Francisco / Katherine Matthay MD, PI / Tiffany Chang MD, Scholar||Center of Excellence Grants||2012||California|
|New Approaches to Neuroblastoma Therapy||Children's Hospital Los Angeles / Robert Seeger||Phase I/II Infrastructure Grants||2008||California|
|131-I-MIBG and Targeted Therapy for Neuroblastoma: Infrastructure Proposal.||University of California San Francisco / Katherine Matthay, MD||Phase I/II Infrastructure Grants||2007||California|
|Synergistic Activity of Anti-GD2 Antibody and CD47-Blockade for Immunotherapy of Neuroblastoma and Osteosarcoma||The Board of Trustees of the Leland Stanford Junior University / Robbie Majzner, MD||'A' Award Grants||2019||California|
|Targeting Aberrant Hh Signaling with BET Bromodomain Inhibition as a Novel Therapeutic Strategy Against MB and DIPG||Lucile Packard Children's Hospital at Stanford University School of Medicine / Yujie Tang, PhD||Young Investigator Grants||2014||California|